In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.

Published Date: 03 Jun 2024

Bentuximab vedotin has significantly less toxicity and is more effective than standard chemotherapy.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL

2.

A study outlines the need for policies that enhance cancer patients' autonomy and information.

3.

The pancreatic ductal adenocarcinoma mRNA vaccine holds promise for preventing relapse.

4.

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

5.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot